Cost-Effectiveness Analysis of Four Antiemetic Schemes for Patients with Lung Cancer Treated with Chemotherapy
- VernacularTitle:肺癌化疗过程中4种止吐方案的成本-效果分析
- Author:
Xuzhen CAI
;
Xiaohua LIN
;
Lina HUANG
;
Chaobiao ZHENG
- Publication Type:Journal Article
- Keywords:
Lung cancer;
Chemotherapy;
Vomiting;
Cost-effectiveness analysis
- From:
China Pharmacy
1991;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the cost-effectiveness among four different antiemetic schemes for prevention vomiting induced by chemotherapy in patients with lung cancer.METHODS:120 patients receiving cisplatin chemotherapy were divided into 4 groups:Ondansetron(Group A),Tropisetron(Group B),Ramosetron(Group C),and Metoclopramide(Group D).The therapeutic effects were monitored and the cost-effectiveness analysis was performed on the four treatment schemes.RESULTS:The effective rates of the four groups were 87.3%,92.7%,90.7% and 61.3% respectively;the cost-effectiveness ratios were 684.77,906.37,222.33 and 45.02,respectively;and the incremental cost-effectiveness ratios of A,B and C group were 2 193.08,2 587.90 and 592.01 respectively as against Group D.CONCLUSION:Ramosetron is the most rational one among the 4 schemes.
